Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Investigation Of Tainted Heparin Could Highlight Need For Import Safety Legislation - Or Not

This article was originally published in The Pink Sheet Daily

Executive Summary

Energy and Commerce Republicans seek to determine who contaminated heparin supplies in 2008, how they did it, and why FDA has failed to answer those questions as the panel begins oversight of the agency.

You may also be interested in...



FDA Drug Shortage Strategy: Heparin Is Test Case For Developing Alternate Sources

Science board encourages agency to address broader economic shortage causes.

FDA Foreign Inspections User Fee Program Getting Push On The Hill

The pharmaceutical industry faces an increasingly aggressive push to create user fees for manufacturing inspections.

FDA Foreign Inspections User Fee Program Getting Push On The Hill

The pharmaceutical industry faces an increasingly aggressive push to create user fees for manufacturing inspections.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel